Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms

doi:10.5306/wjco.v17.i1.112801

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

(28)

(37)

(0)

(8)

(1)

(805)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Clin Oncol. Jan 24, 2026; 17(1): 112801
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.112801

Full Size Figure Download Figure

Figure 2 Treatment outcomes in patients with lymphoproliferative neoplasms (n = 90). Bar chart for treatment outcomes (complete remission, partial remission, refractory, recurrence, death).

Citation: Sherief DE, Nosair N, Abdelhameed AM, Sadaka E, Othman AAA, Elgamal R. Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms. World J Clin Oncol 2026; 17(1): 112801
URL: https://www.wjgnet.com/2218-4333/full/v17/i1/112801.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i1.112801

Sherief DE, Nosair N, Abdelhameed AM, Sadaka E, Othman AAA, Elgamal R. Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms. World J Clin Oncol 2026; 17(1): 112801 [PMID: 41608342 DOI: 10.5306/wjco.v17.i1.112801]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.